(Q37385376)

20 August 2017

1 reference

title

Endocrine therapy for the treatment of postmenopausal women with breast cancer (English)

1 reference

20 August 2017

1 reference

3

Ruth O'Regan

1 reference

20 August 2017

Seema Harichand-Herdt

series ordinal

1

1 reference

PubMed ID

19192957

20 August 2017

Amelia Zelnak

series ordinal

2

1 reference

20 August 2017

1 February 2009

1 reference

Expert Review of Anticancer Therapy

20 August 2017

1 reference

20 August 2017

9

1 reference

20 August 2017

2

1 reference

20 August 2017

187-198

1 reference

Studies on Prostatic Cancer: I. The Effect of Castration, Of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate

20 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

A receptor molecule for estrogens: studies using a cell-free system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Aromatase inhibitors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Fulvestrant (Faslodex): current status in the therapy of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Overview of the main outcomes in breast-cancer prevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Tamoxifen chemoprevention treatment and time to first diagnosis of estrogen receptor-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Tamoxifen, serum lipoproteins and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Phase II Evaluation of Lyl56758 in Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Effects of tamoxifen on benign breast disease in women at high risk for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Goserelin depot in the treatment of premenopausal advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Use of aromatase inhibitors in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Intratumoral estrogen production in breast carcinoma: significance of aromatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Concordance among gene-expression-based predictors for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

A mechanism of drug resistance to tamoxifen in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.187

21 January 2018

Identifiers

DOI

10.1586/14737140.9.2.187

1 reference

20 August 2017

1 reference

PubMed ID

19192957